Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antivipmyn is a polyvalent antivenom composed of F(ab)2 and Fab fragments derived from immunoglobulin G (IgG) antibodies. It is specifically designed to neutralize the venom of various viperid and elapid snakes, including those found in Africa and Latin America. The drug works by binding to venom toxins with its antigen-binding fragments (Fab), thereby neutralizing their toxic effects and facilitating their elimination from the body. By removing the Fc fragment during production, the risk of hypersensitivity reactions such as anaphylaxis or serum sickness is reduced compared to whole IgG antivenoms. The F(ab)2 fragments have improved tissue distribution and faster clearance than whole IgG, allowing for effective neutralization of venom components both within and outside vascular spaces[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antivipmyn.